Andere talen Cabaletta Bio, Inc.

Aandelen

CABA

US12674W1099

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 15-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,69 ^USD	+13,00%		+5,05%	-44,10%

15/05	Cabaletta Bio, Inc. Rapporteert de winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
22/03	CABALETTA BIO, INC. : HC Wainwright herhaalt koopadvies voor het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cabaletta Bio : Corporate Presentation	15/05
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	15/05
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13/05
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	20/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	27/02
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	02/02
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment	01/02
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	01/02
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	01/02
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cabaletta Bio, Inc.

Aandelen

CABA

US12674W1099

Andere talen

Filters